Health
AHA: A Novel Monoclonal Antibody Therapy Cuts LDL Cholesterol by Half in a High-Risk Patient Population, Study Shows – Cath Lab Digest
November 16, 2020 — The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients…
November 16, 2020 The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterolthe so-called bad cholesterolby 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, were presented as late breaking science at the American Heart Association Scientific Sessions 2020 on…
-
Noosa News22 hours agoFour men extradited from Sydney over alleged extortion on the Sunshine Coast
-
Noosa News8 hours agoFormer NRL player Teui ‘TC’ Robati lured woman to pub toilet before alleged rape, jury told
-
Noosa News17 hours agoCattle claimants ‘bitterly disappointed’ after court downplays compensation claim from live export ban
-
General22 hours agoQueensland government to begin social housing rent reviews to free up spaces for those in ‘most need’